# Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

> **NCT02235415** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24526 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Motens® (lacidipine)

## Key facts

- **NCT ID:** NCT02235415
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 1999-09
- **Final completion:** —
- **Target enrollment:** 24526 (ACTUAL)
- **Last updated:** 2014-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02235415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02235415, "Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02235415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*